FDA Approves Tudriqev, a New Melanoma Treatment
My AccountFIND A DOCTORNewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSkin ConditionsSmileSun CareTreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin Lifting and TighteningBodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessFitnessGLP-1sHealthMenopauseBEAUTYPASSNewsView All NewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceView All FaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSkin ConditionsSmileSun CareTreatmentsView All TreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin Lifting and TighteningBodyView All BodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairView All HairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsView All AwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingView All ShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessView All WellnessFitnessGLP-1sHealthMenopauseLoading…FIND A DOCTORBEAUTYPASS Advertisement Home›NewBeauty RX FDA Approves Tudriqev, a New Melanoma Treatment A new option for patients who’ve run out of them. Immunotherapy has become the standard first line of defense against melanoma, the deadliest form of skin cancer, but for a meaningful share of patients, it either doesn’t work or eventually stops working. Until now, options for those patients have been limited. As reported by Dermatology Times, the FDA has granted accelerated approval to a new treatment called Tudriqev, used together with the immunotherapy drug nivolumab, for adults with advanced melanoma that kept progressing despite prior treatment. Ahead, a brief rundown of what to know about Tudriqev, what the trial data shows and more.